Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of two locations we draw on the diverse talents of a 500-strong team. More>

Sanofi and Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). More>

Myozyme® (alglucosidase alfa) Shortlisted for Prix Galien Real World Evidence Award

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that Myozyme® (alglucosidase alfa) has been shortlisted for a Prix Galien medal within the “Real World Evidence” category which recognises excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patients benefits or socio-economic gains. More>

Patients in Scotland denied prostate cancer drug - The SMC has ruled against approving Jevtana® (cabazitaxel) for advanced prostate cancer, despite recent NICE approval

Sanofi Genzyme, the specialty care global business unit of Sanofi, is disappointed with the decision by the Scottish Medicines Consortium (SMC), recommending against the use of Jevtana® (cabazitaxel) on NHS Scotland for the treatment of metastatic hormone-relapsed prostate cancer (mHRPC) and thus denying Scottish patients access to a drug that according to the National Institute for Health and Care Excellence (NICE) is a clinically-effective and cost-effective treatment that prolongs life and is valued by patients. More>


Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.